...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>American Journal of Psychiatry and Neuroscience >Brain atrophy in Multiple Sclerosis
【24h】

Brain atrophy in Multiple Sclerosis

机译：多发性硬化症中的脑萎缩

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Multiple sclerosis (MS) has traditionally been considered to be primarily an inflammatory demyelinating disorder affecting the white matter. Nowadays it is recognized as both an inflammatory and a neurodegenerative condition involving the white and grey matter. Grey matter atrophy occurs in the earliest stages of MS, progresses faster than in healthy individuals, and shows significant correlations with cognitive function and physical disability; indeed, brain atrophy is the best predictor of subsequent disability and can be measured using magnetic resonance imaging (MRI). There are a number of MRI methods for measuring global or regional brain volume, including cross-sectional and longitudinal techniques. Preventing brain volume loss may therefore have important clinical implications affecting treatment decisions, with several clinical trials now demonstrating an effect of disease-modifying treatments (DMTs) on reducing brain volume loss. In clinical practice, it may therefore be important to consider the potential impact of a therapy on reducing the rate of brain volume loss. This article summarizes the knowledge on brain volume in MS.
机译：传统上认为多发性硬化症（MS）主要是影响白质的炎症性脱髓鞘疾病。如今，它被认为是涉及白和灰质的炎性和神经退行性疾病。灰质萎缩发生在MS的最早阶段，其进展速度快于健康个体，并且与认知功能和身体残疾呈显着相关性。实际上，脑萎缩是随后残疾的最好预测指标，可以使用磁共振成像（MRI）进行测量。有许多用于测量整体或区域大脑体积的MRI方法，包括横断面和纵向技术。因此，预防脑容量损失可能对治疗决策具有重要的临床意义，目前已有多项临床试验证明了疾病缓解疗法（DMT）可以减少脑容量损失。因此，在临床实践中，考虑一种疗法对降低脑容量损失率的潜在影响可能很重要。本文总结了有关MS中脑容量的知识。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号